ClinicalTrials.gg
RecruitingNCT07747480Updated Nov 5, 2026

A Sub Study to Investigate the Safety and Tolerability of Aletekitug in Participants With Moderate To Severe Ulcerative Colitis

A Phase 1 interventional study of Aletekitug in Colitis, Ulcerative, sponsored by GlaxoSmithKline. Recruiting at 1 site in United Kingdom. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2026-11-05.

Sponsored by GlaxoSmithKline · Phase 1, Interventional, and Treatment

From the registry’s dates

  • Started Sep 2026; still recruiting 2 months later.
Updated Nov 5, 2026Now RecruitingFirst site in United Kingdom+4 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
16
Allocation
Not applicable
Ages
18 Years to 75 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 16 studies in Colitis, Ulcerative by GlaxoSmithKline — 2 open to participants now, 3 under way, none of them phase 3. Colitis, Ulcerative · GlaxoSmithKline.

Planned enrollment
8th of 15
16 · median 16
Started
2026
with 1 other
Phase 1
10 of 16
2 open now
Registered
15th of 16
by date

Among the 16 studies in Colitis, Ulcerative by GlaxoSmithKline, this one is the 8th largest by planned enrollment of the 15 interventional ones that give a count, is one of 2 that started in 2026, is one of 10 in phase 1, and was the 15th registered.

Colitis, Ulcerative

1,854 studies on the registry are indexed under Colitis, Ulcerative; 473 are open to participants now.

Browse Colitis, Ulcerative studies →

Open to participants now

2 of the 16 studies in Colitis, Ulcerative by GlaxoSmithKline are open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

All 2 open studies →

Who these studies take

Of the 307 Colitis, Ulcerative studies recruiting now, 134 (44%) set no upper age limit and 136 (44%) stop at 75 or younger; 71 take children under 18; 41 take healthy volunteers.

This study: 18 Years to 75 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 16 studies in Colitis, Ulcerative by GlaxoSmithKline, or all of them as a file.
02

Study summary

This goal of this sub-study is to learn how safe and tolerable the study drug, aletekitug (anti-IL-18), in participants with moderately to severely active ulcerative colitis (UC). This study is the sub-study of the platform trial.

03

Conditions studied

  • Colitis, Ulcerative

Keywords

  • Ulcerative Colitis
  • Anti-Interleukin-18 (anti-IL-18)
  • Inflammatory bowel disease
  • Aletekitug
  • GSK1070806
  • Gastrointestinal Diseases
04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Diagnosis of UC for greater than or equal (>=) 3 months before screening. Appropriate documentation of endoscopy and results consistent with the diagnosis of UC must be available.
  • Active UC with a modified Mayo score (mMS) of 5 to 9 points and endoscopy sub score of 2 to 3 within 14 days before baseline biopsy collection.
  • Active disease beyond the rectum (greater than [>]15 centimeter [cm] of active disease from the anal verge at the screening colonoscopy).
  • Documentation of a surveillance colonoscopy (performed according to local standard) within 12 months before screening (may be performed during screening) for participants with pancolitis of >8 years duration or left-sided colitis of >12 years duration, or primary sclerosing cholangitis
  • Demonstrated an inadequate response to, loss of response to, or intolerance to conventional therapy (e.g., oral 5- aminosalicyclic acid [5-ASA] compounds, , thiopurines).
  • May have been receiving a conventional therapy if the prescribed dose has been stable for the required time period before the screening endoscopy.
  • Must meet requirements if a female participant is a woman of (WOCBP)

Exclusion criteria

Exclusion Criteria:

  • Participants with current diagnosis of Crohn's disease (CD) or Inflammatory bowel disease-unclassified (IBD-U) or a history of radiation colitis, microscopic colitis or ischemic colitis. Have currently known complications of UC such as fulminant colitis, or toxic megacolon, stoma, or stricture/stenosis within the small bowel or colon.
  • Have prior history of dysplasia of the gastrointestinal tract or found to have dysplasia, other than completely removed low-grade dysplastic lesions, in any performed during the screening endoscopy.
  • Have a history of malignant neoplasm within the last 5 years.
  • Have history of lymphoproliferative disorder, including lymphoma, or signs and symptoms suggestive of possible lymphoproliferative disease
  • Have any active, chronic, or recurrent infections based on the investigator's assessment.
  • Have history of opportunistic infections within 1 year of screening
  • Have history or presence of significant medical illness including but not limited to cardiovascular, respiratory, gastrointestinal (excluding UC), hepatic, renal, endocrine, hematologic, neurological, and psychiatric disorders capable of significantly altering the absorption, metabolism, or elimination of drugs; constituting a risk when taking the study intervention or interfering with the interpretation of the data.
  • Have evidence of active or latent Tuberculosis (TB) as documented by medical history, examination, and TB testing at Screening:
  • Have significant allergies to humanized monoclonal antibodies.
  • Have multiple or severe drug allergies, intolerance to topical , or severe post-treatment reactions
  • Have had previous colectomy (total or subtotal), or any other manifestation that might require surgery while enrolled in the trial.
  • Have ostomy or ileoanal pouch.
  • Have received any of the following for treatments of UC:

    • Immunomodulatory medications, including cyclosporine, tacrolimus, mycophenolate mofetil, thalidomide, within 4 weeks before screening endoscopy.
    • Topical (rectal) treatment of 5-ASA or corticosteroid enemas/suppositories within 2 weeks of screening endoscopy.
    • Have received approved or advanced therapy (Ats) (i.e., biologics or small molecules including biosimilars).
    • Interferon therapy within 8 weeks before screening endoscopy.
    • Agents that deplete B- or T-cells (e.g., rituximab) within 12 months of baseline. Participants remain excluded if there is evidence of persistent targeted lymphocyte depletion at the time of screening endoscopy.
  • Had Clostridium difficile infection within 30 days of screening endoscopy or have a positive test result at screening, or other intestinal pathogen within 30 days before screening endoscopy.
  • Participant must not have signs of an ongoing infection related to an intestinal pathogen.
  • In the investigator's opinion, any clinically significant abnormalities of laboratory results from chemistry, hematology or urinalysis tests obtained at the screening visit that cannot be attributed to the underlying moderate-to-severe UC.
  • Pregnant or breastfeeding women, or women planning to become pregnant or breastfeed during the study.
  • Positive for or C, (Human Immunodeficiency Virus), as assessed by method available at each site;
  • Uncontrolled hypertension (i.e., blood pressure consistently measures >=140/90 millimeters of mercury (mmHg) while actively taking 1 or more antihypertensive medications).
Terms in these criteria, in plain language(9)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
16 participants (estimated)

Study arms

  • Experimental
    Aletekitug (GSK1070806)

    Participants will receive Aletekitug.

    Biological: Aletekitug

Interventions

  • BiologicalAletekitug

    Aletekitug will be administered.

    Also known as: GSK1070806

06

What researchers measure

Primary outcomes

  1. Number of Participants with Adverse events (AEs)

    Adverse events will be collected.

    Time frame: Up to 34 weeks [End of sub-study (EOSS)]

  2. Number of Participants with Serious AEs (SAEs)

    Serious AEs will be collected.

    Time frame: Up to 34 weeks (EOSS)

  3. Number of Participants who Discontinue Study Intervention due to AEs

    Participants who discontinue study intervention due to AEs will be reported.

    Time frame: Up to 34 weeks (EOSS)

  4. Number of Participants with Clinically Significant Changes in Laboratory Readings

    Hematology, clinical chemistry, and urinalysis will be collected.

    Time frame: Up to 34 weeks (EOSS)

  5. Number of Participants with Clinically Significant Changes in Vital Signs

    Blood pressure, temperature and pulse rate readings will be collected.

    Time frame: Up to 34 weeks (EOSS)

  6. Number of Participants with Clinically Significant Changes in 12-lead Electrocardiogram (ECG) Readings

    ECGs readings will be collected.

    Time frame: Up to 34 weeks (EOSS)

07

Study locations

1 of 1 sites recruiting
  • GSK Investigational Site
    Oxford, OX3 7LE, United Kingdom
    Recruiting
08

References and documents

Individual participant data

Plan to share: Yes — Study Sponsor will assess requests from qualified researchers for anonymized individual patient-level data and related study documents. Data sharing is subject to certain criteria, conditions, and exceptions. For further information, refer to https://www.gsk-studyregister.com/gsk-patient-level-data-sharing-july2025.pdf

Supporting information: Study protocol, Statistical analysis plan, Informed consent form, Clinical study report

Time frame: Anonymized IPD will be made available within 6 months of publication of primary, key secondary and safety results for studies in product with approved indication(s) or asset(s) with development terminated across all indications.

Access criteria: Anonymized IPD is shared with researchers whose proposals are approved by an Independent Review Panel and after a Data Sharing Agreement is in place. Access is provided for an initial period of 12 months, but an extension may be granted, when justified, for up to 6 months.

Data sharing details ↗ · www.gsk-studyregister.com

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Sep 2026 (actual). Primary completion is estimated for Mar 2028, 18 months after the start.

Of 58 industry-sponsored phase 1 interventional studies under Colitis, Ulcerative, half reached primary completion within 12 months of starting (the median), counting those still running; a quarter within 6 and three quarters within 18. This study's planned 18 months is above that.

Counting every sponsor, half of 84 studies reached it within 13 months; a quarter within 8 and three quarters within 26.

Since we started tracking on Sep 25, 2026, the dates moved once, on Nov 5, 2026: start Aug 2026 → Sep 2026, primary completion Jul 2028 → Mar 2028 and completion Dec 2028 → Mar 2028.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Jul 31, 2026
First posted
Aug 5, 2026
StartActual
Sep 3, 2026was Aug 2026
Primary completionEst.
Mar 5, 2028was Jul 2028
CompletionEst.
Mar 5, 2028was Dec 2028
Last update
Nov 5, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Status
Not yet recruiting→Recruiting
changed Nov 5, 2026
Sites
1 site added — first site in United Kingdom
Show site
  • GSK Investigational Site · Oxford, United Kingdom
Nov 5, 2026
Start date
Aug 10, 2026→Sep 3, 2026 (actual)
Nov 5, 2026
Primary completion
Jul 31, 2028→Mar 5, 2028
Nov 5, 2026
Study completion
Dec 4, 2028→Mar 5, 2028
Nov 5, 2026
Show all 1 update
  1. Nov 5, 2026
    Not yet recruiting→Recruiting
    1 site added — first site in United Kingdom
    Show site
    • GSK Investigational Site · Oxford, United Kingdom
    Start date Aug 10, 2026→Sep 3, 2026 (now actual)
    Primary completion Jul 31, 2028→Mar 5, 2028
    Study completion Dec 4, 2028→Mar 5, 2028
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07747480
Lead sponsor
GlaxoSmithKline
Responsible party
Sponsor
First posted
Aug 5, 2026
Start date
Sep 3, 2026
Primary completion
Mar 5, 2028 (estimated)
Completion
Mar 5, 2028 (estimated)
Last update
Nov 5, 2026

Study contacts

US GSK Clinical Trials Call Center
Contact
GSKClinicalSupportHD@gsk.com
877-379-3718
EU GSK Clinical Trials Call Center
Contact
GSKClinicalSupportHD@gsk.com
+44 (0) 20 89904466
GSK Clinical Trials
study director · GlaxoSmithKline

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: GSK1070806

Start the discussion